About / Leadership
Meet the Tilda leadership team
Ram Yalamanchili is the founder and CEO of Tilda Research, where he is focused on building data and operational infrastructure to better execute clinical trials. Previously, he was a founder and CTO at Lexent Bio, which was acquired by Roche, where his team built novel liquid biopsy technologies to help change the way we manage cancer. Prior to Lexent, he was the CEO/Founder of Push Computing, which pioneered predictive security and container technologies for mobile (acquired by MobileIron). Ram began his career as an engineer at VMware and helped architect ESXi hypervisor, which powers the majority of the private cloud infrastructure today. Ram studied Electrical Engineering and Management Science at Carnegie Mellon and Stanford University respectively.
Ram Yalamanchili is the founder and CEO of Tilda Research, where he is focused on building data and operational infrastructure to better execute clinical trials. Previously, he was a founder and CTO at Lexent Bio, which was acquired by Roche, where his team built novel liquid biopsy technologies to help change the way we manage cancer. Prior to Lexent, he was the CEO/Founder of Push Computing, which pioneered predictive security and container technologies for mobile (acquired by MobileIron). Ram began his career as an engineer at VMware and helped architect ESXi hypervisor, which powers the majority of the private cloud infrastructure today. Ram studied Electrical Engineering and Management Science at Carnegie Mellon and Stanford University respectively.
Ram Yalamanchili is the founder and CEO of Tilda Research, where he is focused on building data and operational infrastructure to better execute clinical trials. Previously, he was a founder and CTO at Lexent Bio, which was acquired by Roche, where his team built novel liquid biopsy technologies to help change the way we manage cancer. Prior to Lexent, he was the CEO/Founder of Push Computing, which pioneered predictive security and container technologies for mobile (acquired by MobileIron). Ram began his career as an engineer at VMware and helped architect ESXi hypervisor, which powers the majority of the private cloud infrastructure today. Ram studied Electrical Engineering and Management Science at Carnegie Mellon and Stanford University respectively.
Gaurav Bhatnagar is an accomplished clinical development executive with over 25 years of experience in leading global CROs and biopharma companies. He is passionate about accelerating the development of new therapies through the use of data and technology. Gaurav has transformed clinical trials by pioneering innovations in risk-based monitoring, data-driven feasibility, patient recruitment, and digital/hybrid trial models. His focus on operational excellence and workflow automation has consistently led to faster study startup, improved patient engagement, and reduced costs.
Gaurav Bhatnagar is an accomplished clinical development executive with over 25 years of experience in leading global CROs and biopharma companies. He is passionate about accelerating the development of new therapies through the use of data and technology. Gaurav has transformed clinical trials by pioneering innovations in risk-based monitoring, data-driven feasibility, patient recruitment, and digital/hybrid trial models. His focus on operational excellence and workflow automation has consistently led to faster study startup, improved patient engagement, and reduced costs.
Gaurav Bhatnagar is an accomplished clinical development executive with over 25 years of experience in leading global CROs and biopharma companies. He is passionate about accelerating the development of new therapies through the use of data and technology. Gaurav has transformed clinical trials by pioneering innovations in risk-based monitoring, data-driven feasibility, patient recruitment, and digital/hybrid trial models. His focus on operational excellence and workflow automation has consistently led to faster study startup, improved patient engagement, and reduced costs.
Samba is a seasoned technology leader with over 20 years of expertise in storage, networking, cloud platform development, and product innovation. He played a pivotal role in developing industry-leading solutions at Veritas, VMware, and Diamanti, where he served as a Fellow and led breakthrough innovations in Storage, Kubernetes, and cloud infrastructure. Samba holds a Master’s in Computer Science from IIT Kanpur, India. At Tilda, Samba drives innovation by harnessing AI and cloud technologies to revolutionize clinical trial management. His focus on integrating AI teammates streamlines operations, reduces manual effort, and accelerates critical decisions. Samba’s vision is to remove inefficiencies and empower Sponsors, CROs, sites, and stakeholders across the clinical trial ecosystem to deliver life-changing treatments to patients faster and more effectively
Samba is a seasoned technology leader with over 20 years of expertise in storage, networking, cloud platform development, and product innovation. He played a pivotal role in developing industry-leading solutions at Veritas, VMware, and Diamanti, where he served as a Fellow and led breakthrough innovations in Storage, Kubernetes, and cloud infrastructure. Samba holds a Master’s in Computer Science from IIT Kanpur, India. At Tilda, Samba drives innovation by harnessing AI and cloud technologies to revolutionize clinical trial management. His focus on integrating AI teammates streamlines operations, reduces manual effort, and accelerates critical decisions. Samba’s vision is to remove inefficiencies and empower Sponsors, CROs, sites, and stakeholders across the clinical trial ecosystem to deliver life-changing treatments to patients faster and more effectively
Samba is a seasoned technology leader with over 20 years of expertise in storage, networking, cloud platform development, and product innovation. He played a pivotal role in developing industry-leading solutions at Veritas, VMware, and Diamanti, where he served as a Fellow and led breakthrough innovations in Storage, Kubernetes, and cloud infrastructure. Samba holds a Master’s in Computer Science from IIT Kanpur, India. At Tilda, Samba drives innovation by harnessing AI and cloud technologies to revolutionize clinical trial management. His focus on integrating AI teammates streamlines operations, reduces manual effort, and accelerates critical decisions. Samba’s vision is to remove inefficiencies and empower Sponsors, CROs, sites, and stakeholders across the clinical trial ecosystem to deliver life-changing treatments to patients faster and more effectively
Meet Our Advisors
Dr. Hemmati is Co-Founder and Chief Medical Officer of retina therapeutics company Optigo Biotherapeutics, and also Co-Founder and Chief Scientific Officer of aesthetic medicine company Levation Pharma. Houman has been Chief Medical Affairs Officer of Vyluma. Additionally, he is on the Board of Directors of multiple biotechnology companies, and acts as an advisor in clinical research and drug development. He earned an M.D. from UCLA and a Ph.D. in Biology from the California Institute of Technology (CalTech).
Dr. Hemmati is Co-Founder and Chief Medical Officer of retina therapeutics company Optigo Biotherapeutics, and also Co-Founder and Chief Scientific Officer of aesthetic medicine company Levation Pharma. Houman has been Chief Medical Affairs Officer of Vyluma. Additionally, he is on the Board of Directors of multiple biotechnology companies, and acts as an advisor in clinical research and drug development. He earned an M.D. from UCLA and a Ph.D. in Biology from the California Institute of Technology (CalTech).
Dr. Hemmati is Co-Founder and Chief Medical Officer of retina therapeutics company Optigo Biotherapeutics, and also Co-Founder and Chief Scientific Officer of aesthetic medicine company Levation Pharma. Houman has been Chief Medical Affairs Officer of Vyluma. Additionally, he is on the Board of Directors of multiple biotechnology companies, and acts as an advisor in clinical research and drug development. He earned an M.D. from UCLA and a Ph.D. in Biology from the California Institute of Technology (CalTech).
Dr. Saroj is Chief Business Officer at Ocular Therapeutix. Additionally, as Principal of All Eyes Consulting, LLC, she is an independent biotech consultant with over 20 years of experience focusing on global development and commercialization of drugs and technologies advancing new therapeutics. She has been a significant contributor towards the commercialization of both Lucentis and Eylea, two of the most successful biologic products in the ophthalmology sector. She earned her Doctor of Optometry from the University of California at Berkeley.
Dr. Saroj is Chief Business Officer at Ocular Therapeutix. Additionally, as Principal of All Eyes Consulting, LLC, she is an independent biotech consultant with over 20 years of experience focusing on global development and commercialization of drugs and technologies advancing new therapeutics. She has been a significant contributor towards the commercialization of both Lucentis and Eylea, two of the most successful biologic products in the ophthalmology sector. She earned her Doctor of Optometry from the University of California at Berkeley.
Dr. Saroj is Chief Business Officer at Ocular Therapeutix. Additionally, as Principal of All Eyes Consulting, LLC, she is an independent biotech consultant with over 20 years of experience focusing on global development and commercialization of drugs and technologies advancing new therapeutics. She has been a significant contributor towards the commercialization of both Lucentis and Eylea, two of the most successful biologic products in the ophthalmology sector. She earned her Doctor of Optometry from the University of California at Berkeley.
Dr. Magrath is CEO of Opus Genetics, and was previously CEO of Lexitas Pharma Services. In addition, he is a practicing physician at the Medical University of South Carolina (Charleston). He brings a differentiated set of leadership experiences to accelerate the growth by combining medical and business expertise to deliver innovative, first-in-class medicines that drive shareholder value. Dr. Magrath is both an advisor and board member, helping companies deliver new treatments for patients. He earned his MD from the Medical University of South Carolina, an MBA from The Citadel, and an MS from Johns Hopkins University.
Dr. Magrath is CEO of Opus Genetics, and was previously CEO of Lexitas Pharma Services. In addition, he is a practicing physician at the Medical University of South Carolina (Charleston). He brings a differentiated set of leadership experiences to accelerate the growth by combining medical and business expertise to deliver innovative, first-in-class medicines that drive shareholder value. Dr. Magrath is both an advisor and board member, helping companies deliver new treatments for patients. He earned his MD from the Medical University of South Carolina, an MBA from The Citadel, and an MS from Johns Hopkins University.
Dr. Magrath is CEO of Opus Genetics, and was previously CEO of Lexitas Pharma Services. In addition, he is a practicing physician at the Medical University of South Carolina (Charleston). He brings a differentiated set of leadership experiences to accelerate the growth by combining medical and business expertise to deliver innovative, first-in-class medicines that drive shareholder value. Dr. Magrath is both an advisor and board member, helping companies deliver new treatments for patients. He earned his MD from the Medical University of South Carolina, an MBA from The Citadel, and an MS from Johns Hopkins University.
Stay current on our AI teammates. Sign up now.
@2025, Tilda Research. All rights reserved.
Stay current on our AI teammates. Sign up now.
@2025, Tilda Research. All rights reserved.
Stay current on our AI teammates. Sign up now.
@2025, Tilda Research. All rights reserved.
Stay current on our AI teammates. Sign up now.
@2025, Tilda Research. All rights reserved.